Targeting spike protein-induced TLR/NET axis by COVID-19 therapeutic NRICM102 ameliorates pulmonary embolism and fibrosis.
Wei WC, Liaw CC, Tsai KC, Chiou CT, Tseng YH, Chiou WF, Lin YC, Tsai CI, Lin CS, Lin CS, Liou KT, Yu IS, Shen YC, Su YC.
Wei WC, et al.
Pharmacol Res. 2022 Oct;184:106424. doi: 10.1016/j.phrs.2022.106424. Epub 2022 Sep 5.
Pharmacol Res. 2022.
PMID: 36064077
Free PMC article.
NRICM102 was found to disrupt spike protein/ACE2 interaction, 3CL protease activity, reduce activation of neutrophils, monocytes and expression of cytokines (TNF-alpha, IL-1beta, IL-6, IL-8), chemokines (MCP-1, MIP-1, RANTES) and proinflammatory receptor (TLR4). NRICM102 a …
NRICM102 was found to disrupt spike protein/ACE2 interaction, 3CL protease activity, reduce activation of neutrophils, monocytes and express …